Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a method to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a $73m series A financing, and a deal with Roche which has a potential biodollar value north of $750m, C4 Therapeutics co-founder and executive chair Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?